This vigilance helps ensure any adverse reactions are managed effectively
Tirzepatide has a dual-receptor action, targeting both GLP-1 and GIP, which leads to more significant weight loss compared to Semaglutide, which only targets GLP-1
In 2025, it was also approved to treat chronic kidney disease in patients with Type 2 diabetes
[1] Metformin similarly causes gastrointestinal symptoms, with diarrhea, nausea, and abdominal cramping affecting 10-25% of users, especially when initiating therapy
Wegovy was approved in 2021 for chronic weight management in adults who are obese or overweight and have at least one weight-related condition
And sometimes, drug shortages force people to stop their medication abruptly, or take less than they used to